蔓迪国际递表港交所

Group 1 - The core viewpoint of the article is that Mandi International has submitted an application to list on the Hong Kong Stock Exchange, with Huatai International as its sole sponsor, highlighting its leadership in the Chinese consumer pharmaceutical market focused on skin health and weight management solutions [1] - Mandi International's flagship product, the Mandi series minoxidil hair loss treatment, has ranked first in the Chinese hair loss medication market and the minoxidil drug market for ten consecutive years since 2014, with market shares of approximately 57% and 71% respectively in 2024 [1] - The company launched the Mandi anti-hair loss shampoo in March 2025, which is the first shampoo in China to include the anti-hair loss ingredient Unodex, achieving over 500,000 bottles sold within the first six months, thereby redefining the domestic anti-hair loss and hair care market landscape [1]